Stifel's commentary also mentioned that C.H. Robinson has been considered a "show-me story," indicating that the market has been waiting for proof of the company's performance and strategy ...

Stifel upgraded C.H. Robinson (CHRW) to Buy from Hold with an unchanged price target of $113. The company reported “solid” Q4 results and the ...

Colgate-Palmolive Co (CL) stock saw a decline, ending the day at $89.57 which represents a decrease of $-0.29 or -0.32% from the prior close of $89.86. The stock opened at $90.11 and touched a low of ...

The firm’s CEO cited a “very competitive” recruiting market in 2024, but forecasts a better 2025 as longer-term efforts pay ...

The natural beauty of West Virginia will be celebrated both musically and visually in the Wheeling Symphony Orchestra’s upcoming performance, “Nature. Beauty.” Set for 2 p.m., Feb. 8, at the Capitol ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $125.6, a high estimate of $135.00, and a low estimate of $115.00. This upward trend is evident, ...

Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy. Analyst Price Forecast Suggests 12.29% Upside As of January 28, 2025, the ...

JMP Securities raised the firm’s price target on Stifel Financial (SF) to $135 from $125 and keeps an Outperform rating on the shares. Stifel ...

CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced Getinge off the U.S. market in 2015.